Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyHealth Net Enstilar Coverage & Prior Auth Policy |…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PMN.181

    Calcipotriene/Betamethasone Dipropionate Foam (Enstilar)

    Customize your policy alerts

    Sign up for Health Net Policy CP PMN.181 alerts

    Get alerted when Policy CP PMN.181 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity and prior authorization criteria for Enstilar topical foam for treatment of plaque psoriasis in covered members; applies to Health Net lines of business including Commercial, HIM, and Medicaid where noted.

    Policy Summary
    PayerHealth Net
    PolicyCalcipotriene/Betamethasone Dipropionate Foam (Enstilar)
    Policy CodePolicy CP PMN.181
    Change TypeNo material changes
    Effective Date12.01.18
    Next Review Date
    Key ActionSubmit documentation (office notes, labs or clinical information) showing member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12+years of age minimum for FDA indication
    60 g/4 daysmaximum dosing limit
    Up to 1 monthapproval duration
    60 g, 120 gcan sizes
    NCapplicable state

    Coverage Criteria for Enstilar (Calcipotriene/Betamethasone Foam)

    Initial Approval Criteria — Plaque Psoriasis

    Covered when ALL of the following are met:

    Initial Plaque Psoriasis Criteria: 1) Diagnosis of plaque psoriasis (PsO); 2) Patient is 12 years of age or older; 3) Failure of a medium to ultra-high potency topical corticosteroid (see Appendix B) unless contraindicated or clinically significant adverse effects are experienced; 4) Failure of one of the following unless contraindicated or clinically significant adverse effects are experienced: calcipotriene, calcitriol, or tazarotene; 5) Requested dose does not exceed 60 g every 4 days (7 cans per month)Dose limit: 60 g every 4 days

    Approval duration: 1 month

    Continued Therapy (Plaque Psoriasis)

    Covered for continuation when one of the following is met:

    Continued Therapy Conditions: a) Member is currently receiving the medication via the Centene benefit or has previously met initial approval criteria; b) Member is currently receiving the medication and continuity of care regulations for the state/product apply; AND member is responding positively to therapy; If the request is for a dose increase, the new dose does not exceed 60 g every 4 days (7 cans per month)Dose limit: 60 g every 4 days

    Approval duration: Up to 1 month of total treatment (a single continuous course up to 4 weeks is recommended)

    Other Diagnoses/Indications

    For non-covered or off-label uses

    Other Indications Pathways: 1) For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid): follow the no coverage criteria policy for the relevant line of business (CP.CPA.190 commercial, HIM.PA.33 marketplace, CP PMN.255 Medicaid); OR 2) For drugs NOT on the formulary/PDL: follow the non‑formulary policy for the relevant line of business (CP.CPA.190 commercial, HIM.PA.103 marketplace, CP PMN.16 Medicaid); OR 3) If the drug has had a recent label change (within the last 6 months) or the requested use is not listed and criterion 1/2 do not apply: refer to the off‑label use policy for the relevant line of business (CP.CPA.09 commercial, HIM.PA.154 marketplace, CP.PMN.53 Medicaid)N/A

    Refer to the listed policies

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, CP.PMN.53 for Medicaid) or other evidence of coverage documents.

    For members covered by Medicaid, state Medicaid coverage provisions take precedence when they conflict with this clinical policy; providers should consult the applicable state Medicaid manual for specific coverage requirements and follow those provisions where different from this policy.

    Use of this drug for non‑FDA approved indications without sufficient supporting documentation is considered not authorized. Providers must follow the referenced off‑label use policies and submit clinical evidence per those policies to support any request for coverage of off‑label use.

    Product Coding and Dosing Information

    Product strengths and package sizesmixed
    0.005%/0.064%Can containing 0.005% calcipotriene/0.064% betamethasone dipropionate foam: 60 g, 120 g (2 cans of 60 g)
    Maximum Dose
    Maximum dose (policy limit)60 g every 4 days (maximum described as 60 g/4 days)
    Monthly equivalent noted in criteriaDescribed as up to 7 cans per month when following 60 g/4 days limit
    In-consistent appendix valueAppendix includes alternate maximum value (100 g/week) noted in source appendix text
    Approval duration linked to dosingApproval duration: 1 month (initial); continued therapy up to 1 month with same dose limit)

    Provider Actions, Prior Authorization and Documentation

    Prior Authorization

    Prior authorization required for Enstilar when coverage criteria met

    Prior authorization is required. Enstilar (calcipotriene/betamethasone foam) is considered medically necessary for plaque psoriasis only when the policy's specified criteria are met (diagnosis of plaque psoriasis, patient age ≥12 years, required prior topical therapy failures, and dosing within the stated limit).

    • Approval duration: 1 month for initial therapy; continued therapy approval up to 1 month when continuation criteria are met.
    • Dose limit: does not exceed 60 g every 4 days (7 cans per month).
    Note

    No explicit PA codes or alternate PA requirements stated

    No additional or separate prior authorization codes or alternate prior authorization pathways are specified in the policy text.

    Background on Product and Indication

    Enstilar is a fixed‑combination topical foam that contains a vitamin D analog and a corticosteroid — calcipotriene 0.005% and betamethasone dipropionate 0.064% — indicated for the topical treatment of plaque psoriasis (PsO) in patients aged 12 years and older. Typical administration is topical application to affected areas once daily, with treatment courses generally limited to a single continuous course of up to 4 weeks; providers should avoid use on the face, groin, axillae, areas of skin atrophy, and under occlusive dressings unless directed by a clinician.

    Definitions and Abbreviations

    Enstilar — Product definition and formulation
    Product name (generic)Calcipotriene 0.005% / betamethasone dipropionate 0.064% foam
    Brand nameEnstilar (topical foam)
    Formulation and routeFixed‑combination topical foam containing a vitamin D analog (calcipotriene) and a corticosteroid (betamethasone dipropionate); topical route
    Dosing regimen (per labeling)Apply topically to affected area(s) once daily for up to 4 weeks; avoid face, groin, axillae, areas with atrophy, and occlusive dressings unless directed by provider
    Indication age thresholdIndicated for plaque psoriasis in patients 12 years of age and older
    PsO — Abbreviation

    Revision History

    07.19.24Annual reviewLatest

    4Q 2024 annual review conducted; no significant clinical changes and references reviewed/updated.

    Policy Summary
    PayerHealth Net
    PolicyCalcipotriene/Betamethasone Dipropionate Foam (Enstilar)
    Policy CodePolicy CP PMN.181
    Change TypeNo material changes
    Effective Date12.01.18
    Next Review Date
    Key ActionSubmit documentation (office notes, labs or clinical information) showing member meets all approval criteria.
    SourceLink
    On This Page
    Coverage Criteria for Enstilar (Calcipotriene/Betamethasone Foam)Product Coding and Dosing InformationProvider Actions, Prior Authorization and DocumentationBackground on Product and IndicationDefinitions and AbbreviationsRevision History
    Step Therapy

    Document prior topical failures before approval

    Prior topical therapy failures must be documented: the member must have failed a medium- to ultra‑high‑potency topical corticosteroid and failed one of calcipotriene, calcitriol, or tazarotene unless contraindicated or adverse effects prevent use.

    • Failure of a medium to ultra-high potency topical corticosteroid (see Appendix B for agents and potency guidance) unless contraindicated or intolerant.
    • Failure of one of: calcipotriene, calcitriol (Vectical), or tazarotene unless clinically significant adverse effects or contraindications exist.
    Note

    No other step therapy requirements stated

    The policy does not list any other separate step therapy requirements beyond the prior topical failures already specified.

    Documentation Required

    Required submission: clinical documentation must be provided

    Provider must submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, and other clinical information demonstrating the member meets all approval criteria.

    • Include documentation of diagnosis (plaque psoriasis), patient age, prior topical therapy trials and outcomes, and current dosing.
    • Include notes showing response to therapy for continuation requests.
    Note

    Coverage decisions subject to plan terms and law

    This clinical policy is a guide to medical necessity and used to assist coverage decisions; final coverage and benefit payment remain subject to the member's plan terms, exclusions, limitations, and applicable law.

    • Coverage decisions are subject to the member's evidence of coverage, contract, and applicable state/federal requirements.
    Denial Risk

    Denial risk: insufficient or missing documentation

    Failure to submit the required supporting documentation (office chart notes, lab results, or other clinical information) may result in denial of the prior authorization request.

    Note

    Medicaid precedence: follow state Medicaid provisions when they conflict

    For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this clinical policy; providers must follow applicable state Medicaid manual provisions to avoid coverage differences or denials.

    AbbreviationPsO = plaque psoriasis
    Context of useUsed throughout the policy to denote the FDA‑approved indication for Enstilar (plaque psoriasis)
    Appendix referenceAppendix A lists PsO as the abbreviation for plaque psoriasis